Key facts
- It has raised $1.6M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Changde Caixin Financial Holding, Huada GreenPine Angel Fund, Bangming Capital, Green Startups, Hainan Houshi Private Equity Fund Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for SynBioLab (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for SynBioLab (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SynBioLab (Biotechnology)
Operator of synthetic biology research and development company created to develop the production technology of high-value-added compounds. The company focuses on the biosynthesis of high-value-added plant-derived medicinal compounds, it uses synthetic biology methods to redesign microbial metabolism pathways and build biological cell factories to manufacture high-purity, low-cost, low-polluting, high -value-added drugs, helping its clients greatly reduce the length of the production cycle and the cost of plant-derived compounds in an environmentally friendly way.
- Sector
- Healthcare
- HQ
- Jiaxing, China
- Founded
- 2017
- Employees
- 13
- Website
- synbiolab.cn/
- Ownership
- Privately Held (backing)
SynBioLab (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynBioLab (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynBioLab (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.